Medindia
Medindia LOGIN REGISTER
Advertisement

New Survey Finds Strong Public Interest in Prescription Drug Safety Issues

Thursday, September 20, 2007 General News
Advertisement
Americans Trust FDA, but express conflicting views about how to manage safety risks



WASHINGTON, Sept. 19 /PRNewswire-USNewswire/ -- American University's Center for Congressional and Presidential Studies will announce results tomorrow from a national survey assessing public views on safety of prescription medicines, the Food and Drug Administration (FDA), and overall satisfaction with the U.S. health care system. The survey briefing will take place on Thursday, September 20 from 9:30 - 10:30 AM ET at the National Press Club, First Amendment Lounge, 529 14th Street NW, Washington, DC.
Advertisement



"At a time when Congress is debating the FDA Revitalization Act (FDARA) to strengthen the safety of prescription medicines and overhaul the FDA, this survey validates that drug safety is a real concern for the American public," said Dr. James Thurber, Director, Center for Congressional and Presidential Studies, American University. "The survey shows some support for the concept of FDARA, however, there is a clear desire and expectation among participants for regulators to balance speed of approvals with their responsibility of reducing safety risks."
Advertisement



Key survey findings include:



The national telephone survey of 800 adults was conducted by The Mellman Group and Public Opinion Strategies from September 4-6, 2007. The survey has a margin of error of +/- 3.46%.



To register for the press briefing or for more information, contact Katharine Perrow at 202-955-6222, [email protected].



The survey results will be announced as part of A Dialogue on Prescription Drug Safety: Seeking Common Ground, a program presented by American University's Center for Congressional and Presidential Studies and FORA.tv to examine efforts by public policymakers to enhance America's prescription drug safety systems and reform the FDA.



Future A Dialogue on Prescription Drug Safety: Finding Common Ground forums will feature policy and industry leaders, patient advocates and others to discuss the political realities and medical implications of FDARA. The program is sponsored by American University's Center for Congressional and Presidential Studies and FORA.tv, a provider of online forums, discussions and debates on global political, social and cultural issues. The program is supported by Pfizer Inc.



For more information about A Dialogue on Prescription Drug Safety or upcoming events, please visit www.dialogueondrugsafety.org. or contact Katharine Perrow at 202-955-6222, (832) 549-5873 or [email protected].



About American University's Center for Congressional and Presidential Studies

American University's Center for Congressional and Presidential Studies, a center within the university's School of Public Affairs, provides an integrated teaching, research, and study program focusing on Congress, the presidency, and the interactions of these two basic American institutions. Established in 1979, the Center provides a scholarly organization uniquely able to draw on its Washington, DC location in the very heart of the events shaping Congress and the presidency.



For more information about CCPS, go to www.american.edu/ccps.



About FORA.tv



FORA.tv (www.fora.tv) is the leading provider of online video content focused on discourse, discussions and debates surrounding global political, social and cultural issues. Content partners of FORA.tv include: C-SPAN; the World Affairs Councils of Northern California, Dallas, Oregon, Philadelphia and Connecticut; The Brookings Institution; Hoover Institution; the Cato Institute; New America Foundation; The Heritage Foundation; and the Aspen Institute. FORA.tv delivers content via its proprietary FORA Player, mobile phones, iPods, cable video-on-de
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close